From Surf Wiki (app.surf) — the open knowledge base

2-Fluoromethamphetamine

Stimulant designer drug

Summary

Stimulant designer drug

2-Fluoromethamphetamine (2-FMA) is a stimulant drug of the amphetamine family which has been used as a designer drug. 2-FMA is commonly compared to lisdexamfetamine (Vyvanse), and dextroamphetamine due to its efficacy as a study or productivity aid. 2-FMA is purported to produce somewhat less euphoria than comparable amphetamines, likely due to its main mechanism of action consisting of norepinephrine reuptake inhibition.

Chemistry

2-Fluoromethamphetamine is fluorinated analogue of methamphetamine, and is a regioisomer of 3-FMA and 4-FMA.

It does not activate the serotonin receptors, including 5-HT2A, unlike most stimulant drugs of the amphetamine family.

Legal status

Canada

As of 1996, 2-FMA is a controlled substance in Canada, due to being an analog of methamphetamine.

China

As of October 2015, 2-FMA is a controlled substance in China.

Germany

As of 13 December 2014, 2-FMA is a controlled substance in Germany. It is controlled under Anlage I BtMG (Narcotics Act, Schedule I). Substances controlled under Anlage I BtMG are illegal to manufacture, possess, import, export, buy, sell, procure or dispense without a license. Violations of the law are punishable by a fine or imprisonment for up to five years.

Ukraine

As of July 2019, 2-FMA is a controlled substance in Ukraine (considered a narcotic).

United States

As a close analog of a scheduled controlled substance, sale or possession of 2-FMA could be potentially be prosecuted under the Federal Analogue Act.

References

(April 2010). "Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone". Forensic Science International.
(February 2023). "Identification and Quantitative Analysis of 2-Fluoromethamphetamine and Its Metabolites in Human Urine". Journal of Analytical Toxicology.
(December 2020). "In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT_1A, and 5-HT_2A receptors-On-target receptor potency and efficacy, and off-target effects". Forensic Science International.
Legislative Services Branch. (2022-03-31). "Consolidated federal laws of Canada, Controlled Drugs and Substances Act".
(27 September 2015). "关于印发《非药用类麻醉药品和精神药品列管办法》的通知". China Food and Drug Administration.
"Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften – Vom 5. Dezember 2014". Bundesanzeiger-Verlags-GmbH.
"Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz – BtMG) Anlage I (zu § 1 Abs. 1) (nicht verkehrsfähige Betäubungsmittel)".
"Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz – BtMG) § 29 Straftaten".
(23 July 2019). "Про внесення змін до Закону України "Про обіг в Україні наркотичних засобів, психотропних речовин, їх аналогів і прекурсорів"". Verkhovna Rada of Ukraine.
(March 2005). "Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs)". Forensic Science International.
"Federal Controlled Substance Analogue Act Summary". Erowid Analog Law Vault.

Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

designer-drugs methamphetamines 2-fluorophenyl-compounds norepinephrine-dopamine-releasing-agents organofluorides

Want to explore this topic further?

Ask Mako anything about 2-Fluoromethamphetamine — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report